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Abstract
Background: Haematological changes associated with malaria in pregnancy are not well documented, and have
focused predominantly on anaemia. Examined here is thrombocytopaenia in pregnant women infected with
Plasmodium falciparum or Plasmodium vivax in a low transmission area on the north-western border of Thailand.
Methods: In this observational study we reviewed the platelet counts from routine complete blood count (CBC)
in a cohort of healthy and malaria infected Karen pregnant women attending weekly antenatal clinics. A platelet
count of 75,000/μL was the threshold at 2 standard deviations below the mean for healthy pregnant women used
to indicate thrombocytopenia. Differences in platelet counts in non-pregnant and pregnant women were
compared after matching for age, symptoms, malaria species and parasitaemia.
Results: In total 974 pregnant women had 1,558 CBC measurements between February 2004 and September
2006. The median platelet counts (/μL) were significantly lower in patients with an episode of falciparum 134,000
[11,000–690,000] (N = 694) or vivax malaria 184,000 [23,000–891,000] (N = 523) compared to healthy pregnant
women 256,000 [64,000–781,000] (N = 255), P < 0.05 for both comparisons. Plasmodium falciparum and P. vivax
caused a 34% (95% CI 24–47) and 22% (95% CI 8–36) reduction in platelet count, respectively. Pregnant compared
to non pregnant women were at higher risk OR = 2.27 (95%CI 1.16–4.4) P = 0.017, for thrombocytopaenia.
Platelets counts were higher in first compared with subsequent malaria infections within the same pregnancy.
Malaria associated thrombocytopaenia had a median [range] time for recovery of 7 [2-14] days which did not
differ by antimalarial treatment (P = 0.86), or species (P = 0.63) and was not associated with active bleeding.
Conclusion:  Pregnant women become more thrombocytopenic than non-pregnant women with acute
uncomplicated malaria. Uncomplicated malaria associated thrombocytopaenia is seldom severe. Prompt
antimalarial treatment resulted in normalization of platelet counts within a week.
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Background
Pregnancy increases susceptibility to malaria[1] and is
associated with profound alterations in the fibrinolytic
and coagulation systems [2]. While normal pregnancy
produces physiological changes resulting in a procoagu-
lant effect (to minimize intrapartum blood loss) [2],
malaria [3], in particular severe malaria caused by Plasmo-
dium falciparum, can cause profound anaemia, thrombo-
cytopaenia, activation of the coagulation cascade and
rarely disseminated intravascular coagulopathy [4]. The
extent of these changes in cases of uncomplicated malaria
in pregnancy has not been previously described.
Methods
The Shoklo Malaria Research Unit (SMRU) has been con-
ducting antenatal clinics (ANCs) in refugee camps on the
Thai-Burmese border since 1986 and in clinics for migrant
women since 1998. ANCs provide pregnant women with
early malaria detection, by weekly blood smear, and
prompt treatment of malaria to prevent maternal death.
Malaria transmission is low and seasonal in the area and
there is a high prevalence of multi-drug resistant strains of
Plasmodium falciparum [5] and chloroquine sensitive P.
vivax. There are no effective drugs for prophylaxis in preg-
nancy and randomized controlled trials with bed nets and
skin repellents given specifically for pregnant women,
failed to show a significant preventive effect [6,7]. Attend-
ance at ANC is voluntary and all women are encouraged
to attend weekly. Since the inception of this programme
there have been no maternal deaths from malaria in
women who attend weekly, where previously malaria
related maternal mortality was of the order of 1,000/
100,000 live births [8]. Anaemia is monitored every two
weeks and prophylactic and treatment doses of ferrous
sulphate and folic acid are provided until delivery.
Women are encouraged to come and deliver under super-
vision in the SMRU facilities. Complicated deliveries
requiring Caesarean section are referred to Mae Sot hospi-
tal (one hour drive).
Women with malaria are routinely asked about symptoms
and assessed for spleen and liver size. All cases with posi-
tive malaria smears are treated: falciparum or mixed infec-
tions receive quinine sulphate 10 mg/kg three times a day
for seven days or artesunate 2 mg/kg once per day for
seven days, where possible, in combination with clin-
damycin 300 mg three times daily for seven days. Plasmo-
dium vivax infections are treated with 25 mg base/kg of
chloroquine given over three days (10, 10, 5 mg base/kg/
day).
Since 2004, it has been possible to offer pregnant women
a complete blood count (CBC) as part of routine care dur-
ing a malaria attack and (in some sites) at booking consul-
tation. CBC is repeated within the same patient if
clinically indicated e.g. to monitor thrombocytopaenia
[9]. Women with reduced platelet counts have them
rechecked at 48 hours and the CBC is only repeated again
(at day 7 and 14) if they have not normalized. As part of
routine antenatal care, blood pressure is checked on
admission, at any episode of malaria or other illness, and
at 28, 32, 34 and 36 weeks and then weekly until delivery.
In order to compare CBC data in pregnant and non-preg-
nant women, using the same automated haematology
analyzer as used for pregnant women, data from 71 non-
pregnant women of child bearing age, median [range] 25
years [15–45] years) with symptomatic uncomplicated
falciparum malaria from the same population were ana-
lysed [10]. These were compared to a selected group of
108 pregnant women febrile with acute uncomplicated
falciparum malaria, and the first infection for the preg-
nancy of any species of malaria Pregnant women with
asymptomatic infection detected by the active weekly
screening were excluded as they were not thought to be
comparable.
Laboratory samples and processing
Blood smears (thin and thick films) were prepared using
Giemsa staining and were read for 200 fields before being
declared negative. Parasite counts were reported per 500
white blood cells (WBC) and for counts above 1,000 par-
asites per 500 WBC by the percentage of infected red cells
(RBC). All stages of the parasites were recorded (asexual
and gametocytes).
A 2 ml sample of venous blood was placed in an EDTA
tube, refrigerated and transported on ice to SMRU Mae Sot
laboratory, where the complete blood count was deter-
mined using a Sysmex pocH-100i automated haematol-
ogy analyzer. Quality control of the Sysmex pocH-100i
was determined on a daily basis by analysis of three differ-
ent manufacturer-provided samples with known cell
counts.
Definitions
Thrombocytopaenia in pregnancy was defined by a plate-
let count lower than 75,000/μL. This is the value
(rounded up to the nearest 5,000) that falls two standard
deviations below the mean platelet count in healthy
Karen pregnant women (mean 198,000/μL, SD: 62,500,
min-max [22,000–540,000], n = 723) from a previously
published cohort study from the same area [11]. This
value was used for three reasons: 1) the definition used for
thrombocytopaenia in pregnant women varies in the liter-
ature e.g. 115,000/μL [12-14], 150,000/μL [15] and
75,000/μL [9], 2) pregnancy itself causes platelet count to
decrease[9] and 3) the original cohort included healthy
pregnant women of all gestations[11] and there was no
significant difference with platelet count by trimester.Malaria Journal 2008, 7:209 http://www.malariajournal.com/content/7/1/209
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Healthy women were defined as pregnant women without
malaria or other febrile illness at booking consultation.
Asymptomatic malaria was defined by the presence of
asexual forms of P. falciparum or P. vivax on the micro-
scopic examination of the peripheral blood in a pregnant
women with no elevation of temperature (aural <
37.5°C), no history of fever or any of the following symp-
toms: headache, dizziness, joint pain, anorexia, nausea,
spontaneous bleeding. Symptomatic malaria was defined
as the presence of an elevated temperature (aural ≥
37.5°C), or a history of fever in the previous two days,
with one or more of the above symptoms in a pregnant
women together with asexual forms of Plasmodium on the
microscopic examination of the peripheral blood.
Uncomplicated malaria was defined by the absence of
signs of severity (WHO criteria[16]) and uncomplicated
hyperparasitaemia by 4% parasitized red blood cells or
more in a patient with no sign of severity. Hypertension
was defined as a blood pressure of 140/90 mmHg or more
with or without proteinuria. Eclampsia was defined as
hypertension and proteinuria detected for the 1st time
after 20 weeks gestation.
Estimated gestational age (EGA) at the time of CBC was
determined from ultrasound (US) dating of the preg-
nancy. As part of routine ANC pregnant women had a US
scan at booking and at 18 weeks. Splenomegaly was
recorded as present when the spleen was palpable below
the costal margin and was measured in cm. Hepatomegaly
was recorded as present when the liver was palpable
below the costal margin in the mid-clavicular line.
Statistical analysis
Continuous normally distributed data were described by
the mean (standard deviation) and non-normally distrib-
uted data by the median [range]. Percentages were given
for categorical data. Categorical data were compared using
the Chi-square test or by Fisher's exact test, as appropriate.
Student's t-test was used to analyze means, the Mann-
Whitney test was used to analyze medians. The Wilcoxon
rank sum test was performed on continuous data with a
skewed distribution for paired analysis to determine
whether there were significant differences of parasitaemia
and haematological counts after or between episodes of
malaria. Forward and backward stepwise logistic regres-
sion was used to assess the relationship with thrombocy-
topaenia, while controlling for demographic
characteristics (age), and potential confounding factors
significant on univariate analysis (parasitaemia, gesta-
tional age at time of CBC, symptoms, fever and spleen size
as appropriate). Age, and log transformed parasitaemia
were treated as a continuous variables and the others
(fever: temperature ≥ 37.5°C, pregnancy status) as dichot-
omous variables. Data were analyzed using EpiInfo ver-
sion 6, and SPSS version 14 for Windows (SPSS Inc).
Results
Between February 2004 and September 2006, 974 preg-
nant women had 1,558 CBC measurements. CBC results
were available for 255 healthy women from their antena-
tal booking consultation (all these women had a negative
blood smear), 694 acute P. falciparum episodes, 523 P.
vivax episodes, and 86 were repeat measurements follow-
ing a report of thrombocytopaenia (Figure 1). There were
more episodes than there were women in the cohort. Fig-
ure 2 presents possible scenarios of CBC measurements
within a single pregnancy and highlights the considerable
variation in the possible sequence and gestation of
malaria episodes (Figure 2).
Co-infections of falciparum with vivax malaria (n = 49)
showed similar haematological changes to falciparum
monoinfections but were excluded from analysis in order
to focus on the effects of P. falciparum and P. vivax sepa-
rately.
The proportion of uncomplicated malaria episodes was
97.9% (1,191/1,217) and 2.1% (26/1,217) were hyper-
parasitaemic episodes (≥ 4% RBC parasitized). The three
groups (Healthy, first episode P. falciparum and first epi-
sode P. vivax) were comparable for age, gravidity and par-
ity at the time of the first CBC (Table 1). Estimated
gestational age at the time of the CBC was significantly
lower (P = 0.001) in the healthy group as this was done at
the booking consultation and malaria is more likely to
occur in the 2nd trimester of pregnancy. The gestation at
each episode of malaria, P. falciparum or P. vivax, was com-
pared with the platelet count and no significant associa-
tion was evident (Spearman Rho 0.012 and 0.001; P =
0.0756 and P = 0.980, respectively) (Figure 3). Overall
2.7% (26/974) of women required blood transfusion dur-
ing pregnancy or immediately post-partum of whom 85%
(22/26) were transfused for malaria related symptomatic
anaemia.
As eclampsia is typically associated with thrombocytopae-
nia we reviewed the 1.3% (13/964) of women with hyper-
tension in pregnancy individually. As the CBC for malaria
was measured earlier in pregnancy than the hypertension
developed, particularly for women with a diagnosis of
eclampsia (n = 3), and these women were not thrombocy-
topenic their CBC results were not excluded from the
malaria analysis.
Malaria species, symptoms, hepatosplenomegaly and 
parasitaemia
On admission, falciparum cases had significantly higher
parasitaemia, days of fever, proportion febrile or sympto-
matic, and higher rates of enlarged spleen and liver, com-
pared to vivax cases (Table 2). The proportion of episodes
of malaria with any symptoms, history of fever in the lastMalaria Journal 2008, 7:209 http://www.malariajournal.com/content/7/1/209
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two days or fever on admission was 76.2% (927/1,217)
and significantly higher for P. falciparum (81%, 563/694)
than for P. vivax (70%, 364/523) episodes, P = 0.001.
(Table 2). More women with splenomegaly had thrombo-
cytopaenia than those without a palpable spleen: 25.3%
(19/75) vs 11.2% (124/1,106), P = 0.001. Splenomegaly
was associated with a 2.7 (95%CI: 1.5–4.7) fold risk of
thrombocytopaenia. The number of women who had
spontaneous bleeding at the time of the malaria episode
such as nose bleeds or gum bleeding was very small, and
not significantly associated with thrombocytopaenia (OR
= 1.95, 95%CI 0.65–5.82, P = 0.226). There was no differ-
ence in the proportion of reported antepartum haemor-
rhage (APH) in women who had any episode of
thrombocytopaenia, 23% (5/22), compared to those who
had none, 18% (114/622, P = 0.60). The geometric mean
parasitaemia was significantly lower in afebrile compared
to febrile patients (485/μL and 9,957/μL, respectively, P =
0.001), and asymptomatic episodes compared to sympto-
matic episodes (218/μL and 1,385/μL, respectively, P =
0.001). Geometric mean parasitaemia of P. falciparum was
higher than that of P. vivax: 2,176/μL and, 273/μL respec-
tively, P = 0.001.
Effect of malaria on platelet count
Platelet counts (median, [range]/μL) in episodes of
malaria infection, P. falciparum 134,000 [11,000–
690,000] and P. vivax 184,000 [23,000–891,000]/μL,
were significantly lower compared to healthy controls,
256,000 [64,000–781,000]/μL, P < 0.05 for both compar-
isons. The platelet counts in falciparum cases were signif-
icantly lower than in vivax cases, P < 0.05. The proportion
of women with thrombocytopaenia, were healthy 0.8%
(2/255), falciparum 17.7% (123/694) and vivax 5.0%
(26/523), P < 0.05 for both comparisons.
There were no cases of severe (< 10,000/μL) thrombocyto-
paenia (lowest platelet count = 11,000/μL in the falci-
parum group). In the remaining cases, there were 51.7%
(78/151) counts from 10,000 to < 50,000/μL and 48.3%
(73/151) count from 50,000 to < 75,000/μL. There was
no association between species of infection and having a
count of 10,000 to < 50,000/μL or 50,000 to < 75,000/μL
(P = 0.866, data not shown). A parallel trend was
observed between parasitaemia and thrombocytopaenia
for falciparum and vivax cases (Figure 4). The proportion
of asymptomatic malaria episodes with thrombocytopae-
nia was 4.0% (6/151). These cases were all P. falciparum
infections.
Quantification of impact of malaria infection on platelet 
count in individual patients
There were 60 women who had their first CBC at enrol-
ment (healthy) and then a subsequent CBC for a malaria
Flow diagram of the various stages of analysis showing the number of CBCs available in terms of malaria episodes or in partic- ular women Figure 1
Flow diagram of the various stages of analysis showing the number of CBCs available in terms of malaria epi-
sodes or in particular women.
1,558 CBC in 974 women
P. vivax
N=523 episodes
P.falciparum
N=694 episodes
Repeat CBC for 
thrombocytopaenia 
N=86 episodes
Symptomatic  episodes
P.falciparum 81%  N=563
P. vivax 70% N=364
Paired analysis i.e. 
enrolment CBC and 
subsequent episode of 
P.falciparum or P.vivax 
N=60 women
Matched comparison to non-pregnant women of 
reproductive age i.e. febrile, 1st episode in 
pregnancy, uncomplicated P.falciparum
N=108  women
Enrolment (healthy) 
N=255 women
Recovery from malaria induced 
thrombocytopaenia            
N=56 womenMalaria Journal 2008, 7:209 http://www.malariajournal.com/content/7/1/209
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Schematic diagram of typical examples of pregnancy follow-up in individual patients and when CBC samples could have been  collected Figure 2
Schematic diagram of typical examples of pregnancy follow-up in individual patients and when CBC samples 
could have been collected.
•Enrolment CBC available at 2 ANC sites.
•Weekly malaria smear, every 2nd week haematocrit, until delivery.
•Treatment of all positive P.falciparum and/or P.vivax.
•CBC if P. falciparum or P. vivax
•Repeat CBC (if platelet count < 75,000 / μL) at 48hr, again 7days (no repeat if normal)
Routine 
ANC
DELIVERY
Each blocked
row represents
an example of
typical pregnancy
follow-up at ANC
CBC on enrolment (healthy) and never malaria
Enrolment
CBC on enrolment and at PF and PV
Enrolment PF PV
PF at enrolment and CBC done
PF*
No CBC on enrolment, CBC at 2 episodes PF
PF PF
No CBC on enrolment, CBC at 3 episodes PV 
PV* PV* PV
CBC on enrolment, CBC at PF & for low platelet count
Enrolment PF* & Repeat CBC
234
MONTHS OF PREGNANCY
9 5678 1
-Start of shaded 
block represents 
possible CBC 
sampling point
-* Symptomatic 
infection
Table 1: Characteristics of Karen and Burmese women at the time of their first CBC in pregnancy
Healthy Plasmodium falciparum Plasmodium vivax
N = 255 N = 425 N = 294
Maternal Age, yrs 25 25 25
[15–46] [14–43] [15–42]
EGA (weeks) 14.0 19.6 22.1
[4.3–39.4] [4–41.2] [4–40]
Gravidity 3 [1–14] 3 [1–13] 3 [1–11]
Parity 1 [0–10] 2 [0–11] 1 [0–9]
Proportion primigravidas % (n) 26 (65/255) 24 (103/425) 28 (81/294)
Data are median and [range] unless otherwise indicated.
No difference in primips proportions (P = 0.605).Malaria Journal 2008, 7:209 http://www.malariajournal.com/content/7/1/209
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episode (P. falciparum = 24 or P. vivax = 36). Platelet
counts all decreased with malaria, the impact of P. falci-
parum  being significantly greater than that of P. vivax
(Table 3). The median thrombocytopenic effect of malaria
species was estimated from baseline (healthy) counts as a
reduction of 34%, (95% CI: -24 to -47) for falciparum
cases and a reduction of 22% (95% CI: -16 to -29) for
vivax cases, respectively (Table 3).
The relationship between gestational age and platelet count for Plasmodium falciparum and P. vivax infection Figure 3
The relationship between gestational age and platelet count for Plasmodium falciparum and P. vivax infection.
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Table 2: Malaria episode details and symptoms in Karen and Burmese pregnant women according to species
Plasmodium falciparum Plasmodium vivax
Geometric mean [range] parasitaemia/μL 2,288 [6–569,634] 273 [1–82,934]
Median episode number 1 [1–9] 1 [1–10]
Median EGA, weeks 22.4 [4–42] 24.3 [5–40.6]
Proportion with splenomegaly 10.5 (66/628) 2.0 (8/399)
Median [range] spleen size, cm 3 [1–13] 3 [1–4]
Proportion with hepatomegaly 15.7 (99/630) 5.8 (23/399)
Median [range] liver, cm 3 [1–9] 2 [1–5]
Proportion of asymptomatic episodes 18.9 (131/694) 30.4 (159/523)
Proportion febrile (admission) 27.6 (180/652) 10.8 (52/482)
Proportion women with a history of fever 58.6 (407/694) 28.5 (149/523)
Median days of fever 2 [1–30] 2 [1–9]
Proportion headache 58.0 (393/678) 45.7 (233/510)
Proportion dizziness 34.9 (237/679) 34.9 (178/510)
Proportion joint pain 38.1 (259/679) 34.7 (177/510)
Proportion anorexia 35.8 (243/678) 23.7 (121/510)
Proportion nausea 26.7 (181/679) 22.5 (115/510)
Please note that headache, dizziness, joint pain, anorexia and nausea symptoms were not recorded for 16 and 13 episodes of falciparum and vivax, 
respectively.Malaria Journal 2008, 7:209 http://www.malariajournal.com/content/7/1/209
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Effect of repeated episodes of malaria in pregnancy on 
thrombocytopaenia
The proportion of women who had multiple episodes of
malaria was 49% (381/781). A second episode occurred
in 27% (214/781), a third in 11% (85/781), and 4 or
more episodes in 10% (82/781). In falciparum malaria
cases, the proportion of women with thrombocytopaenia
was higher in the first episode 22%, (80/356), compared
to later episodes of P. falciparum 13% (43/338), OR = 2.0
(95%CI 1.3–3.0), P = 0.001, and this was also observed
for vivax malaria: 11% (30/279) versus  3% (6/238),
respectively, OR = 2.9 (95%CI 1.2–7.4), P = 0.018.
The relationship between parasitaemia and platelet count for Plasmodium falciparum and P. vivax infection in pregnancy Figure 4
The relationship between parasitaemia and platelet count for Plasmodium falciparum and P. vivax infection in 
pregnancy.
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Table 3: Paired analysis of haematological parameters: booking consultation (healthy) and at the first episode of malaria
Species (N) Parameter Median min max P*
P. falciparum (N = 24) Platelet Baseline (healthy)/μL 256,000 115,000 419,000 < 0.001
Reduction from baseline/μL -86,000 -305,000 -5,000
% difference (95%CI) -34 (-24 to -47)%
Haemoglobin Baseline (healthy) g/dL 11.2 9.9 14.2 0.005
Reduction from baseline g/dL -0.3 -3.3 1.9
% difference (95%CI) -3 (-2 to -4)%
WBC Baseline (healthy)/μL 9,900 4,500 13,900 0.070
Reduction from baseline/μL -1,250 -6,400 3,100
% difference (95%CI) -13 (-9 to -18)%
P. vivax (N = 36) Platelet Baseline (healthy)/μL 242,000 101,000 438,000 < 0.001
Reduction from baseline/μL -52.5 -376 129
% difference (95%CI) -22 (-16 to -29)%
Haemoglobin Baseline (healthy) g/dL 11.4 8.9 12.9 0.031
Reduction from baseline g/dL -0.6 -2.4 1.2
% difference (95%CI) -5 (-4 to -7)%
WBC Baseline (healthy)/μL 8,900 1,300 24,00 < 0.001
Reduction from baseline/μL -750 -16,600 11,800
% difference (95%CI) -8 (-6 to -12)%
*P paired analysis of reduction from baselineMalaria Journal 2008, 7:209 http://www.malariajournal.com/content/7/1/209
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Recovery from thrombocytopaenia following treatment 
for malaria in pregnancy
Data on women who had malaria and a repeat CBC due
to thrombocytopaenia were limited to 56 women. The
median [range] time for recovery from thrombocytopae-
nia was 7 [2-14] days (N = 56) and this did not differ
between species (P = 0.632). The median time for recovery
from thrombocytopaenia did not vary with the drug (qui-
nine, artesunate, chloroquine) used for treatment (P =
0.858) (Figure 5).
Thrombocytopaenia in pregnant and non-pregnant 
reproductive age women
CBC data from 71 non-pregnant women of child bearing
age, median [range] 25 years [15–45] years) with uncom-
plicated falciparum malaria from the same population
[10] were compared to 108 pregnant women whose
malaria episode was febrile, uncomplicated falciparum,
and the first of any species of infection for the pregnancy.
A significantly greater proportion of pregnant women
were thrombocytopenic 47% (51/108) than non-preg-
nant women 26% (18/70, P = 0.004). There was no differ-
ence in the proportion of women with splenomegaly
between pregnant 7.4% (8/108), and non-pregnant
women, 12.7% (9/71); P = 0.24. Pregnant women had
significantly higher geometric mean parasitaemia than
non-pregnant women: 13,810 [10–569,634] versus 6,628
[53–176,594]/μL, P = 0.012. A multivariate analysis con-
trolling for independent factors such as the parasitaemia
found that both pregnancy (OR = 2.27, 95%CI 1.16–4.4,
P = 0.017) and parasitaemia (OR = 1.64, 95%CI 1.12–
2.39, P = 0.011) were significant independent risk factors
for thrombocytopaenia.
Pregnancy outcomes
Overall 76.0% (740/974) of women had documented
deliveries, 5.7% (56/974) aborted and 18.3% (178/974)
of women were lost to follow up before the pregnancy
outcome was known mostly because they moved from the
study area. Twins accounted for 0.7% (5/740) of deliver-
ies. There were 1.5% (11/740) of women who had a cae-
sarean section, all for obstetric indications and none as a
result of thrombocytopenic haemorrhage. There were
69.5% (511/735) of singletons weighed in the first 3 days
of life. The mean ± SD [range] birth weight was 2,868 ±
458 [1,200–4,200] g and mean gestational age 39.5 ± 1.6
[28.0–44.4] weeks. There was no significant difference in
mean birth weight or gestational age at delivery in women
with malaria who had or did not have thrombocytopae-
nia reported during pregnancy (data not shown). The rate
of post-partum haemorrhage (PPH), 2.0% (10/503), was
low. PPH in women with malaria occurring less than 5
days before delivery compared to ≥ 5 days was 2.9%% (2/
69) vs 1.2% (6/501), P = 0.25. The two women with PPH
and malaria both had P. vivax infection and both were pla-
centa negative having started treatment 1 day and 4 days
prior to delivery.
Discussion
The observational data presented here demonstrates, as
others have for non-pregnant patients, the reduction in
platelet count associated with both falciparum and vivax
Cumulative percent of thrombocytopaenia recovery by day platelet count was measured and drug treatment Figure 5
Cumulative percent of thrombocytopaenia recovery by day platelet count was measured and drug treatment. 
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malaria [3,17-20]. In this cohort, approximately one in
five episodes of falciparum malaria and one in 20 epi-
sodes of vivax malaria were associated with significant
thrombocytopaenia. The degree of thrombocytopaenia
associated with malaria in pregnancy is likely to have been
underestimated. The weekly screening for malaria in the
ANC[8] in this setting is a very active process of case find-
ing and it will often detect infection before women are
symptomatic. This is unlike the standard case manage-
ment method described by WHO as one of the package of
interventions for control of malaria in pregnancy[21]
where women arrive to the clinic because they have symp-
toms and are treated.
Reduced platelet counts during malaria infection result
from platelet activation, splenic pooling, and a decreased
platelet life-span to 2–3 days (from normal 7–10 days)
[4,17]. The role of immunological factors remains uncer-
tain as the reduction in platelet count is directly propor-
tional to disease severity, and recovers promptly with
recovery from the infection[22]. Pregnancy itself can also
cause thrombocytopaenia for reasons that are not fully
understood [9]. The rate of platelet recovery following ini-
tiation of treatment for malaria is reported variably as
between 4 to 10 days but differs with the severity of
malaria and antimalarial treatment prescribed [23-25]. In
pregnant women, a median time to platelet recovery of
seven days was observed. Platelet recovery time was not
affected by the type of antimalarial drug treatment.
Thrombocytopaenia in malaria was usually asympto-
matic. Very few women reported spontaneous bleeding at
the time of acute infection and bleeding was not signifi-
cantly associated with platelet counts. None of the
malaria cases were affected by autoimmune thrombocyto-
paenia of pregnancy [9] as 100% of women showed
recovery after treatment. The birth weight and gestation
were not significantly affected by these episodes or throm-
bocytopaenia.
In this population of pregnant women with low premuni-
tion (similar to non-immune travelers), there was an
approximate reduction in platelet count by one third in P.
falciparum and one fifth in P. vivax infections. Another
important finding was that thrombocytopaenia, although
uncommon, was also seen in asymptomatic malaria
infected women with P. falciparum. This has recently been
reported in children in Nigeria [26].
Nearly 50% of women in this cohort had subsequent
malaria infections. The risk of thrombocytopaenia was
greatest in the first infection compared to later infections
but one cannot determine whether this is a protective
effect gained by a single infection or a by product of inten-
sive weekly screening where parasitaemia may be detected
earlier and before the woman becomes symptomatic.
Does this level of thrombocytopaenia put women with
malaria at the time of delivery at risk of post-partum
haemorrhage? Spontaneous bleeding is uncommon
unless the platelet count falls below 10,000/μL [27] when
any patient would be treated with platelet transfusion.
This is in keeping with the observations reported here of
no association with APH or spontaneous bleeding with
thrombocytopaenia. Adequate haemostasis with sponta-
neous vaginal delivery and caesarean section can take
place at concentrations above 50,000/μL [14]. Where
facilities exist obstetricians have a tendency to transfuse
platelets at concentrations below 50,000/μL when elective
caesarean section is planned. In this cohort, 52% of
thrombocytopaenia associated with malaria occurred
with platelet counts below 50,000/μL, but none were
below 10,000/μL. In resource rich settings, obstetric prac-
tice is pre-emptive and few women deliver with platelet
counts known to be between 10–50,000/μL without
platelet transfusion. The risk of haemorrhage associated
with normal vaginal delivery in women with a platelet
count in this range is unknown. So the risk of post-partum
haemorrhage for the 50% of episodes of thrombocytopae-
nia that are below 50,000/μL cannot be answered conclu-
sively.
Clearly treatment with antimalarials leads to platelet
recovery but this takes closer to seven days than 48 hours.
This implies it would probably be detrimental to try to
postpone labour in women with treated uncomplicated
malaria at term to allow for platelet recovery with treat-
ment. This may well not apply to severe malaria where
platelet counts are likely to be more severely affected, and
there is a high risk of both fetal and maternal death[4].
The women presented here reside in an area of low and
unstable malaria transmission where acute symptomatic
malaria can occur in women of all gravida [8] and placen-
tal malaria at delivery is uncommon [28]. In sub-Saharan
Africa, adverse affects in primigravida are pronounced and
high rates of placenta malaria 26% (5–52%) are reported
[29-31]. However the change in platelet counts in preg-
nant women with chronic infections has not been deter-
mined. An attempt was made to quantify blood loss at
delivery in women with placental malaria in Tanzania but
it was not possible to measure platelet counts [32]. An
observational study reported a greater risk of PPH in
malaria transmission areas of PNG [33]. Ideally a trial that
could account for malaria infection (peripheral and pla-
centa), platelet count and post-partum haemorrhage in a
higher transmission area is needed to positively determine
if the thrombocytopaenic effects of malaria are directly
associated with PPH.
Falciparum and vivax malaria adversely affect platelet
count in pregnancy and pregnant women are more sus-Malaria Journal 2008, 7:209 http://www.malariajournal.com/content/7/1/209
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ceptible to thrombocytopaenia than non-pregnant
women. The effect of chronic malaria infection in preg-
nancy on thrombocytopaenia is unknown. Nevertheless
treatment results in recovery from thrombocytopaenia
and where efforts to prevent malaria fail, prompt detec-
tion and treatment, particularly in the last week before
delivery should be provided.
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